Trial Profile

A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VK 5211 (Primary)
Indications Hip fracture
Focus Therapeutic Use
Sponsors Viking Therapeutics

Most Recent Events

01 Oct 2018 Results presented in the Viking Therapeutics media release.
01 Oct 2018 According to a Viking Therapeutics media release, data from this trial was presented at the American Society for Bone and Mineral Research (ASBMR) 2018 annual meeting.
17 Jul 2018 According to a Viking Therapeutics media release, data from this trial will be presented at the American Society for Bone and Mineral Research (ASBMR) 2018 annual meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com